N/A N=21 Psoriasis Inflammation and Systemic Co Morbidities
Psoriasis
Primary: Change in Histology
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=11 Interleukin-1 Trap to Treat Autoinflammatory Diseases
Inflammation · Familial Mediterranean Fever · Still's Disease, Adult-Onset
Primary: Mean Change in Daily Scores — -3.09 units on a scale
N/A N=22 Inflammation, Proteolysis and IL-1 Beta Receptor Inhibition in Chronic Hemodialysis Patients
End Stage Renal Disease
Primary: High Sensitivity C-reactive Protein (hsCRP) — 4.67; 15.11 mg/dl — p=0.008
N/A N=4,561 Chronic Gastrointestinal Sequelae of an Acute Outbreak of Bacterial Gastroenteritis in Walkerton Ontario
Irritable Bowel Syndrome
Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants
Phase 3 N=47 Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Familial Cold Autoinflammatory Syndrome (FCAS) · Familial Cold Urticaria · Muckle-Wells Syndrome (MWS)
Primary: Change From Baseline to Week-6 (Part A) Endpoint in Mean Key Symptom Score (KSS) — 2.4; 3.1; 2.1; 0.5 Units of a Scale — p=<.0001
N/A N=15 Autoimmune Protocol Diet and Inflammatory Bowel Disease
Crohn Disease · Ulcerative Colitis · Inflammatory Bowel Diseases
Primary: Number of Participants With Clinical Remission for Crohn's Disease — 6 Participants
Phase 2 N=3 Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency
Gastrointestinal Inflammation Associated With CVID · CVID Enteropathy
Primary: Number of Participants With Increase in Infection or Serious Adverse Events (SAEs) Related to Single Dose Administration of Ustekinumab — 0 participants
N/A N=119 Exercise and Inflammation in the Elderly
Inflammation · Insulin Sensitivity
Primary: Insulin Sensitivity — 50.2; 40.7; 57.5; 42.3 μmol/kgFFM/min
Phase 2 N=6 Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)
DIRA
Primary: Number of Subjects Who Maintained Inflammatory Remission With Rilonacept — 6 Participants
N/A N=33 Imaging Biomarkers in Crohn's Associated Spondyloarthritis
Crohn's Disease · Spondyloarthritis
Primary: Number of Participants With MRI Positivity- Global Assessment Positive — 4; 0 Participants
Phase 3 N=123 Cardiovascular Inflammation Reduction Trial - Inflammation Imaging Study
Vascular Inflammation · Atherosclerotic Cardiovascular Disease
Primary: Change in Arterial Inflammation — 0.03; 0.20 percent change
Phase 2 N=25 Treating Inflammation in Polycystic Ovary Syndrome to Ameliorate Ovarian Dysfunction
Polycystic Ovary Syndrome
Primary: Aim 1: HCG-stimulated Testosterone Area Under the Curve — 4458; 7775 Nonograms*Hour per Deciliter (ng*hr/dL) — p=<0.004
Phase 2 N=15 Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra)
Chronic Kidney Disease · Cardiovascular Disease
Primary: Change in the Concentration of High Sensitivity C-Reactive Protein (hsCRP) From Baseline to 12 Weeks — -2.6; 0.8 mg/dl — p=0.03
Phase 4 N=74 An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels.
Gout
Primary: Number and Percentage of Participants With Evidence of Chronic Ongoing Synovial-Based Inflammatory Disease at Baseline. — 63 Participants — p=0.34
N/A N=100 Inflammation and the Metabolic Syndrome in Humans
Metabolic Syndrome X
Primary: The Primary Outcome Measure is Plasma Levels of TNF Alpha. — 507 ng/mL
N/A N=39 Anti-Inflammatory Treatment of Schizophrenia
Schizophrenia
Primary: Change in Persistent Positive Symptoms — 13; 14; 14; 14 units on a scale
Phase 2 N=80 Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy
Chronic Inflammatory Demyelinating Polyneuropathy
Primary: Number of Participants With Survival — 66; 64 Participants
N/A N=4 Dietary Soy Isoflavones In Chronic Pancreatitis
Chronic Pancreatitis
Primary: Dose Limiting Toxicities — 0; 0; 0; 0 Participants
N/A N=25 Diet and Systemic Inflammation
Low-grade Chronic Inflammation · Intestinal Permeability · Type 2 Diabetes Mellitus
Primary: Fasting Plasma C-reactive Protein — 0.91; 1.07; 1.67; 1.09 mg/L — p=0.403
Phase 4 N=31 Centocor Microarray Study of Patients
Rheumatoid Arthritis · Psoriatic Arthritis · Psoriasis
Primary: Baseline (Wk 0) Disease Activity Score (DAS28) — 4.54; 6.03 Score
N/A N=326 A Study of Moderate to Severe Inflammatory Bowel Disease, Including Ulcerative Colitis (UC) and Crohn's Disease (CD)
Inflammatory Bowel Diseases · Colitis, Ulcerative · Crohn Disease
Primary: Percentage of Participants With Active CD at Day 1 — 45.3 percentage of participants
Phase 2 N=18 Targeting Oxidative Stress in Chronic Beryllium Disease
Chronic Beryllium Disease
Primary: Change in Beryllium Lymphocyte Proliferation Responses (BeLPT) From Baseline to Week 6 — 48.61; 9.33; 22.07; 3.8 Stimulation index
Phase 4 N=280 Anti-inflammatory Effects of Colchicine in PCI
Coronary Artery Disease
Primary: Percent Change in Post-procedural IL-6 Concentration From Baseline to 30 Min -1 hr After PCI — 0; 20 % change — p=0.31
N/A N=266,890 The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study
Venous Thromboses · Venous Thromboembolism · Deep Vein Thrombosis
Primary: Risk of Venous Thromboembolism (VTE) — 335; 845; 132; 3804 Participants
N/A N=4,485 Post Marketing Surveillance Study of Remicade in Patients With Chronic Inflammatory Diseases (P04840)
Arthritis, Rheumatoid · Spondylitis, Ankylosing · Arthritis, Psoriatic
Primary: Number of Participants Experiencing at Least One Adverse Event — 609 Participants
N/A N=43 Association Between Increased Oxidative Stress, Anti-Inflammatory Fatty Acid Formation, and Airway Infection in People With Asthma and Chronic Obstructive Pulmonary Disease
Asthma · Pulmonary Disease, Chronic Obstructive
Primary: 8-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma — 292.4; 421.8 pg/ml
Phase 4 N=18 Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU)
Urticaria Chronic
Primary: Time to 50% Decline in Clinical Symptoms Measured by the Urticaria Activity Score Seven Day(UAS7) — 23; 12 days
N/A N=128 Inflammation and the Heart
Rheumatoid Arthritis
Primary: Left Ventricular Mass Indexed to BSA, g/m^2 — 43.8; 42.2 g/m^2
Phase 2 N=18 Anakinra for Inflammatory Pustular Skin Diseases
Sneddon-Wilkinson · Acrodermatitis Continua of Hallopeau · Pustular Psoriasis
Primary: Number of Participants Treated With Anakinra Who Achieve 50% Disease Improvement by the End of Week 12, as Measured by Total Body Surface Area Involvement (TBSAI50) — 7…
Phase 4 N=81 Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients
Inflammatory Bowel Disease (IBD)
Primary: Measure Antibody Concentrations in Immunosuppressed IBD Patients Who Receive High Dose and Standard of Care Dose Influenza Vaccine — 160; 160; 160; 160 Antibody Titer